Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival
about
PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human gliomaCD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Increased seroreactivity to glioma-expressed antigen 2 in brain tumor patients under radiation.A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.High expression and frequently humoral immune response of melanoma-associated antigen D4 in gliomaCirculating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas.Preliminary study of thyroid and colon cancers-associated antigens and their cognate autoantibodies as potential cancer biomarkers.Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas.Prognostic and diagnostic value of spontaneous tumor-related antibodiesSerological identification of URGCP as a potential biomarker for glioma.Diagnostic potential of zinc finger protein-specific autoantibodies and associated linear B-cell epitopes in colorectal cancer.Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients.Expression of PHF20 protein contributes to good prognosis of NSCLC and is associated with Bax expression.Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Usage of cancer associated autoantibodies in the detection of diseaseIdentifying autoantibody signatures in cancer: a promising challenge.Serum autoantibodies as biomarkers for early cancer detection.Autoantibodies in cancer: prognostic biomarkers and immune activation.Cancer immunoediting in malignant glioma.CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell lineA Unique pH-Dependent Recognition of Methylated Histone H3K4 by PPS and DIDO.PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4.Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.Serum GFAP autoantibody as an ELISA-detectable glioma marker.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
P2860
Q24594648-519FC9E5-CD97-4BC3-82D7-00CFA648F42DQ24615166-1996E1C8-F5BA-40FC-9ADC-5D4C3FD6901BQ26740520-C67C56BC-B2BE-4399-A524-601952ED623BQ28078539-D2C115FC-3B1D-47BC-978E-EEB3074AB68DQ33334409-A2D39334-0A83-43E7-A00B-9AAEC56DD783Q33609458-E16EAB30-B22F-46FB-A536-8563440786C7Q33686433-758C6600-6CBF-464C-A81A-CA4A4A5BB1D2Q33789543-342950E8-E1D6-4EC9-BF5C-5EA3144AFC26Q33802891-75A72EA4-8F79-4E04-B31F-A4CD523C9759Q33890619-BDBA1FDB-D1C8-437F-867D-2BBAEF46BD90Q34276070-FB9E3898-0BC9-4810-9E93-44A567930ED1Q34439167-FA9CF6F1-DAC7-47E9-BE40-5B175358C32CQ34475795-7278F5C8-3905-4FEC-9C49-E7338800E883Q35059607-BEB5744C-CCD4-4FB2-86B3-F7F5216245C9Q35394661-19B51EFF-CB83-4334-A418-6FBFFD38CFECQ35955393-33E67E01-087B-467D-90FD-D7AE65AB9AD3Q36375060-DB4E4B67-5E54-44DC-8EBC-30D4587B7F45Q37014134-D2B890C5-BD2B-4CC7-82F5-B3DEB161D83AQ37217734-6CF58D91-3995-479B-900E-4154B023ABA3Q37579900-6D7A804B-DE3A-41EE-9C4B-A8A8BB1FE1CCQ37622471-A5F6EA8D-DE24-47A0-AF69-9933C9623F81Q37945787-AE91C264-17DA-4ABF-8C96-EDC2D6417920Q37986999-C967E78C-A7AA-40B3-B037-03633CE1EBB5Q39303777-04E9DD1A-F0DB-4F20-9C38-EE4B15B2C4D1Q42370510-5D75280B-BDC1-4A17-95D7-8DE861F0A83CQ47789004-6FEB6FA8-6D0D-43B8-AF43-46E02B4A853DQ49922514-E7030244-26A3-4C85-BDB7-92F73C023B63Q50130464-E75DBE80-AFF8-4594-84E2-ABBB3B43E0C4Q51066755-8E78897E-18E4-492C-8288-DAD7510CE54BQ52683991-83DB3E9A-EADF-4ED8-862A-F2DFEF1569BE
P2860
Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@ast
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@en
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@nl
type
label
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@ast
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@en
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@nl
prefLabel
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@ast
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@en
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@nl
P2093
P3181
P356
P1476
Autoantibodies against GLEA2 a ...... elated with prolonged survival
@en
P2093
Angela Munnia
Anne-Katrin Struss
Eckart Meese
Jochem König
Ulrike Fischer
Wolf-Ingo Steudel
P3181
P356
10.1002/IJC.20929
P407
P577
2005-11-10T00:00:00Z